Pfizer-licensed Cardiovascular Drug Reduces Triglycerides in Phase II

A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.